Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAMTS5 | Q9UNA0 | 6/20 | 0.88 |
| ▸ | PIM1 | P11309 | 5/20 | 0.80 |
| ▸ | PIM2 | Q9P1W9 | 5/20 | 0.80 |
| ▸ | AKR1B1 | P15121 | 4/20 | 0.79 |
| ▸ | CNR1 | P21554 | 1/20 | 0.66 |
| ▸ | IGF1R | P08069 | 1/20 | 0.65 |
| ▸ | HPGD | P15428 | 2/20 | 0.63 |
| ▸ | MMP3 | P08254 | 1/20 | 0.60 |
| ▸ | MMP13 | P45452 | 1/20 | 0.60 |
| ▸ | MAOA | P21397 | 1/20 | 0.58 |
| ▸ | MAOB | P27338 | 1/20 | 0.58 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5509719 | 1.00 | ADAMTS5 (0.88) | ADAMTS5PIM1PIM2AKR1B1CNR1 | |
| SCHEMBL7558360 | 0.94 | ADAMTS5 (1.00) | ADAMTS5PIM1PIM2AKR1B1CNR1 | |
| SCHEMBL7558356 | 0.94 | ADAMTS5 (1.00) | ADAMTS5PIM1PIM2AKR1B1CNR1 | |
| SCHEMBL1250346 | 0.89 | PIM1 (1.00) | ADAMTS5PIM1PIM2AKR1B1CNR1 | |
| SCHEMBL2548389 | 0.89 | PIM1 (1.00) | ADAMTS5PIM1PIM2AKR1B1CNR1 | |
| SCHEMBL1250348 | 0.89 | PIM1 (1.00) | ADAMTS5PIM1PIM2AKR1B1CNR1 | |
| SCHEMBL1248971 | 0.88 | AKR1B1 (1.00) | ADAMTS5PIM1PIM2AKR1B1HPGD | |
| SCHEMBL1248969 | 0.88 | AKR1B1 (1.00) | ADAMTS5PIM1PIM2AKR1B1HPGD | |
| SCHEMBL12891780 | 0.88 | AKR1B1 (1.00) | ADAMTS5PIM1PIM2AKR1B1HPGD | |
| SCHEMBL1247917 | 0.84 | AKR1B1 (0.81) | ADAMTS5PIM1PIM2AKR1B1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1781271-A1 | ARYLIDENES FOR THE TREATMENT OF ESTROGEN RELATED RECEPTOR-ALPHA MEDIATED DISEASES | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-09 | — | — | EP | claimed |
| WO-2006019741-A1 | ARYLIDENES FOR THE TREATMENT OF ESTROGEN RELATED RECEPTOR-ALPHA MEDIATED DISEASES | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-02-23 | — | — | WO | claimed |
| US-20060014812-A1 | Use of estrogen related receptor-modulating aryl ethers | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-01-19 | — | — | US | claimed |
| EP-1781271-A1 | ARYLIDENES FOR THE TREATMENT OF ESTROGEN RELATED RECEPTOR-ALPHA MEDIATED DISEASES | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-09 | — | — | EP | disclosed |
| WO-2006019741-A1 | ARYLIDENES FOR THE TREATMENT OF ESTROGEN RELATED RECEPTOR-ALPHA MEDIATED DISEASES | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-02-23 | — | — | WO | disclosed |
| US-20060014812-A1 | Use of estrogen related receptor-modulating aryl ethers | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014812-A1 | Use of estrogen related receptor-modulating aryl ethers | ESR2, ESRRG, GPER1 | ADAMTS5 4399/4885PIM1 4500/4885PIM2 4143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.